Previous Article | Next Article 
Journal of Virology, June 1999, p. 5034-5042, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Suppression of a Fusion Defect by Second Site
Mutations in the Ecotropic Murine Leukemia Virus Surface
Protein
Tatiana
Zavorotinskaya and
Lorraine M.
Albritton*
Department of Microbiology and Immunology,
University of Tennessee
Memphis, Memphis, Tennessee 38163
Received 16 November 1998/Accepted 5 March 1999
 |
ABSTRACT |
Entry of ecotropic murine leukemia virus initiates when the
envelope surface protein recognizes and binds to the virus receptor on
host cells. The envelope transmembrane protein then mediates fusion of
viral and host cell membranes and penetration into the cytoplasm. Using
a genetic selection, we isolated an infectious retrovirus variant
containing three changes in the surface protein
histidine 8 to
arginine, glutamine 227 to arginine, and aspartate 243 to tyrosine.
Single replacement of histidine 8 with arginine (H8R) resulted in
almost complete loss of infectivity, even though the mutant envelope
proteins were stable and efficiently incorporated into virions. Virions
carrying H8R envelope were proficient at binding cells expressing
receptor but failed to induce cell-cell fusion of XC cells, indicating
that the histidine at position 8 plays an essential role in fusion
during penetration of the host cell membrane. Thus, there is at least
one domain in SU that is involved in fusion; the fusion functions do
not reside exclusively in TM. In contrast, envelope with all three
changes induced cell-cell fusion of XC cells and produced virions that
were 10,000-fold more infectious than those containing only the H8R
substitution, indicating that changes at positions 227 and 243 can
suppress a fusion defect caused by loss of histidine 8 function.
Moreover, the other two changes acted synergistically, indicating that
both compensate for the loss of the same essential function of
histidine 8. The ability of these changes to suppress this fusion
defect might provide a means for overcoming postbinding defects found in targeted retroviral vectors for use in human gene therapy.
 |
INTRODUCTION |
Newly assembled ecotropic murine
leukemia virus (MLV) particles begin their life cycle by infecting
naive host cells. The host cell plasma membrane presents a barrier to
this invasion, and it is the function of the envelope proteins of these
retroviruses to overcome that barrier. The envelope surface protein
(SU) begins performing this task by binding the virus receptor,
securely attaching the virion to the host cell. In addition to
anchoring the virion, the interaction between SU and the receptor
triggers changes in the structure of the envelope transmembrane protein
(TM). These conformational changes activate the fusion potential of TM
primarily by inducing the stretch of hydrophobic residues on its amino
terminus to flip outward into the host cell membrane (6).
Intrusion of this "fusion peptide" in the plasma membrane promotes
the formation of a "fusion pore" through which the virus core
passes to enter the host cell cytoplasm (6). Thus, virions
lacking envelope proteins in their membranes cannot penetrate the host
cell membrane and are noninfectious.
Ecotropic MLV envelope protein is the product of the viral
env gene. Synthesized as a polyprotein, each molecule of
envelope protein (Env) contains a number of glycosylation sites and a
short signal peptide that is removed cotranslationally by the signal peptidase. Following glycosylation, the 85-kDa Env precursor
oligomerizes, and a second internal cleavage processes it into mature
SU and TM molecules. A disulfide bridge between SU and TM retains
molecules of SU in the oligomers. Vesicles transport the resulting
heterotrimers to the plasma membrane where they are assembled into
budding virus particles.
The first 250 residues in SU of ecotropic MLV Env have been identified
as a region that is essential for receptor binding. (Note that the
nucleotide sequence is numbered according to the work of Shinnick et
al. [29] for Moloney MLV [accession no. J02255].
Amino acid residues are numbered from 1 beginning with the alanine on
the amino terminus of mature SU after cleavage of the signal peptide
and beginning with the glutamate on the amino terminus of TM after
cleavage of the precursor protein.) Within this domain, aspartate 84 and a pair of arginines at positions 83 and 95 appear to be critical
for receptor recognition, as their mutation abolishes virus binding
(3, 16). In Env of PVC-211, a neuropathogenic variant of
Friend MLV (FrMLV), the amino acids corresponding to Moloney MLV
(MoMLV) residues 115 and 127 are crucial for the expanded host range of
that virus, although the changes found at these positions do not appear
to affect receptor recognition (16, 19).
Traversing the plasma membrane 14 times, the receptor for the ecotropic
MLV normally functions as the principal transporter of cationic amino
acids in the cell. Sequences in the third extracellular loop of the
receptor-transporter provide the attachment site recognized by SU
(1). The sequence of this loop varies widely between species. The versions found in mouse and rat cells function as ecotropic retrovirus binding sites, explaining why only rodent cells
are susceptible (2). Replacement of two critical residues in
this binding site produced a binding-defective receptor that failed to
provide an effective entry for infectious MLV. Moreover, replacement of
the corresponding two positions in the homologous human cationic amino
acid transporter with the residues found in the mouse protein resulted
in acquisition of receptor function (1).
We are seeking to identify key functional residues on Env, particularly
those that interact with the critical residues identified in the virus
receptor. During virus replication, the viral polymerase reverse
transcriptase (RT) frequently introduces nucleotide changes into the
genome that produce variants known as quasispecies. The very high
particle-to-infectious-unit ratio typically found in ecotropic
retrovirus stocks (24, 25) might be due in part to
generation of mutant Env. Analysis of these naturally occurring env sequences might lead to identification of important
residues in Env. Moreover, it might be possible to influence the
env sequences present in quasispecies by passaging the virus
on cells expressing a binding site mutant of the receptor. Virus that
acquired an envelope mutation compensating for the changes present on
the receptor would have a selective advantage. Identification of the positions altered in such an adapted envelope protein would reveal important functional residues in Env.
We passaged replication-competent MLV on cells expressing
binding-defective receptors and then isolated the env genes
of representative quasispecies present after this selection, determined
their DNA sequence, and deduced the encoded Env sequence. Analysis of
the role of residues altered in the envelope proteins from one of the
quasispecies revealed an essential role for the histidine at position 8 in virus-cell fusion. Thus, there is at least one domain in SU that is
involved in fusion; the fusion functions do not reside exclusively in
TM as was previously thought. Replacement of two residues distant from
histidine 8 on the peptide chain (glutamine 227 and aspartate 243)
suppressed the defect caused by substitution at position 8, suggesting
that the three residues might be near each other in the folded protein.
Furthermore, the suppression was synergistic, indicating that changes
in glutamine 227 and aspartate 243 compensate for the loss of the same
essential function of that residue. These results also suggest that in
the proper context, one or more of these SU residues might participate in virus penetration of the host cell membrane. Their ability to
restore functional loss of the critical histidine residue makes the
substitutions at positions 227 and 243 candidates for suppressing postbinding defects found in targeted retroviral vectors for gene therapy.
 |
MATERIALS AND METHODS |
Cell lines and viruses.
Mouse NIH 3T3 fibroblasts and
nonpermissive human 293 fetal kidney cells (gift of M. Quinlan) were
cultured in Dulbecco's modified Eagle's medium (DMEM). The
293-derived stable transfectants expressing the binding-defective
receptor from cDNAs M-38 and H-63, described elsewhere (17),
were maintained in DMEM containing 200 µg of G418 (GIBCO) per ml. XC
rat sarcoma cells (ATCC CCL-165) were cultured in DMEM supplemented
with 3.5 mg of D-glucose per ml. Recombinant,
replication-competent ecotropic DHFR-5HE* virus produced by cells
expressing the pMLV DHFR*-5 infectious clone was obtained from H. Stuhlmann. The genome of this virus consists of insertion of a small
expression cassette for the mutant dihydrofolate reductase gene
(dhfr) that confers resistance to the drug methotrexate into
the 3' long terminal repeat of ecotropic MoMLV (30). Naive NIH 3T3 cells were exposed to DHFR-5HE* virus stock and selected for
growth in 150 µM methotrexate (Sigma), and then
methotrexate-resistant colonies were pooled to generate producer cell
lines. All experiments reported here were performed with virus from the
DHFR-5HE*1 producer line.
Plasmids.
pcDNA MoMLV was constructed to provide
gag, pol, and wild-type or mutant env
genes for virus particle assembly as follows. The 8-kbp
BssHII-ClaI fragment from plasmid pPEM-5 (gift of
V. Garcia [20]) encoding gag, pol, and the 5'
end of env genes of a MoMLV proviral genome lacking the
packaging signal was ligated to the ClaI-BamHI
fragment encoding the 3' end of MoMLV env of pMov3 (gift of
H. Stuhlmann [11]) into which a BamHI site
was engineered immediately after the env gene termination
codon. This genome was then inserted into the HindIII
and BamHI sites of the eukaryotic expression vector pcDNA3
(Invitrogen), placing the viral structural and enzymatic genes under
the control of the cytomegalovirus promoter. The pBAG plasmid encoding
a packageable MoMLV genome lacking gag, pol, or
env sequences but containing the Escherichia coli
lacZ gene under the control of the retroviral 5' long terminal
repeat and the neomycin resistance gene under the simian virus 40 promoter was the gift of C. Cepko (31). Plasmid encoding
wild-type or mutant envelope proteins, pcENV-Mo, was constructed by
inserting the NdeI-EcoRI restriction fragment of
pcDNA MoMLV containing nucleotide 5403 through the envelope protein
stop codon into expression vector pcDNA3.
Sequence analysis of 5HE virus env gene and isolation
of env genes from virus quasispecies.
Genomic DNA from
the DHFR-5HE*1 virus producer cell line was isolated as previously
described (2) and used as a template for PCR. Two
overlapping fragments of the env gene were amplified with
Pfu thermal polymerase (Stratagene), gel purified, and
submitted to sequence analysis with the Exo(
) Pfu Cyclist
kit (Stratagene). For quasispecies env genes, genomic DNA
was isolated from virus-producing cells precisely as previously
described (2) and used as a template for PCR to amplify
env genes present after virus passaging. Oligonucleotides used for PCR were 5'-CAAAGTAGACGGCATCGCAGCTTGG-3' and
5'-GGCGAATTCATCTATGGCTCGTACTCT-3'. Products were subcloned
into the pcDNA MoMLV plasmid and used to produce virus particles as
described below. Selected plasmids were submitted to DNA sequence analysis.
Virus production.
Clonal populations of human 293 cells
stably expressing the pBAG plasmid were analyzed for
-galactosidase
expression by staining with chromogenic substrate (X-Gal
[5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside]), and the five clones developing the most intense staining in the shortest period of time, indicative of high levels of transcription of
the BAG virus genome, were selected as virus producers. Expression of
packageable viral RNA was confirmed by Northern analysis (data not
shown). One of these cell clones, H1-BAG, was used in all experiments
reported here. To produce lacZ-transducing virus particles, we transiently transfected the H1-BAG cells with pcDNA MoMLV DNA containing wild-type, cloned, or mutated env genes.
Transfection was performed by calcium phosphate precipitation as
described by Sambrook et al. (28). Virus preparations were
freed of producer cells by low-speed centrifugation followed by
filtration through a 0.45-µm-pore-size filter. An aliquot of 3 ml was
stored at
80°C and later used for virus titration. Virus from the
remaining 7 ml was immediately pelleted as described below for
immunoblotting. For each virus binding experiment, the entire virus
preparations were frozen and concentrated as described below.
Site-directed mutagenesis of env genes.
Nucleotide substitutions in the env gene were generated by
the method described by Kunkel (14). For this purpose, we
subcloned the 1,300-bp, HpaI-HpaI restriction
fragment from the MoMLV env gene on plasmid pMOV3
(11) into vector M13mp18 containing an engineered
HpaI site. Site-directed mutagenesis was performed, and the
HpaI-HpaI restriction fragment was transferred
back to pcDNA MoMLV. The entire 1,300-bp fragment in the resulting
plasmid was sequenced with the fmol sequencing kit (Promega) to ensure the absence of unscheduled substitutions and to confirm the presence of
desired mutations.
RT assay and virus titers.
RT assays were performed exactly
as described by S. Goff and coworkers (10). Cells exposed to
stocks of DHFR-5HE* during virus passaging were grown in medium
containing 150 µM methotrexate (Sigma) for 2 weeks to select for
infected cells. Endpoint dilution titration of all virus stocks was
performed as previously described for ecotropic MLV (17).
Western blot analysis.
Virus particles were pelleted from 7 ml of cell-free virus supernatant though a cushion of 25% sucrose in
TNE (10 mM Tris [pH 8.0], 1 mM EDTA, 100 mM NaCl) in a Beckman SW-41
rotor (30,000 rpm, 2 h, 4°C). Pellets were taken up in 40 µl
of phosphate-buffered saline (PBS) and stored at
80°C. Virus
producer cells were lysed immediately after virus harvests in RIPA
buffer (20 mM Tris [pH 7.0], 1% Triton X-100, 0.05% sodium dodecyl
sulfate [SDS], 0.5% sodium deoxycholate, 150 mM NaCl, 2.5 mM
phenylmethylsulfonyl fluoride) by incubation for 30 min on ice. Cell
lysates were centrifuged for 10 min at 10,000 rpm in an Eppendorf model
5415C centrifuge to pellet nuclei, and supernatants were frozen at
80°C. Total protein concentration in cell lysates was determined by
the Bradford assay (Bio-Rad). Ten microliters of virus pellets or 100 µg of total protein from cell lysates was diluted 1:1 in 2× gel
loading buffer (28), boiled for 10 min, chilled on ice, and
then subjected to SDS-polyacrylamide gel electrophoresis and
transferred onto nitrocellulose membranes (Protran [Schleicher & Schuell]). Envelope proteins (SU and precursor) were detected with
goat anti-Rauscher-gp70 (1:100), structural capsid protein (CA) was
detected with goat anti-Rauscher-p30 (1:10,000; Quality Biotech, Inc.),
and envelope TM protein was detected with rabbit anti-p15E antiserum
(1:1,000; gift of Alan Rein). Subsequent incubation with mouse
anti-goat or mouse anti-rabbit antibody conjugated to horseradish
peroxidase (1:10,000; Sigma) was performed, and immunoblots were
developed by detection of horseradish peroxidase with SuperSignal (Pierce).
Virus binding assays.
Binding assays were performed
essentially as described previously (7, 13) with the
following modifications. Virus was concentrated 10- to 15-fold on
Centriplus-100 concentrators (Millipore) to provide binding under
saturating conditions (34a) and to eliminate most of the
monomer SU should any be shed from virions or the producer cell
surface. To ensure that cells were incubated with equal numbers of
particles from each of the virus stocks, the volumes of the
concentrated virus were adjusted to achieve comparable particle
concentrations based on the RT activity and Western blot quantitation
of capsid protein. 293 cells expressing wild-type virus receptor or
parental 293 cells were detached from culture plates with PBS
containing 0.02% EDTA. Cells (106) were then incubated
with 1 ml of adjusted concentrated virus stocks containing equal
amounts of virions in the presence of Polybrene (5 µg/ml) for 1 h at 4°C. Cells were then washed with PBA (PBS, 2% fetal bovine
serum, and 0.02% sodium azide) and incubated in 500 µl of PBA
containing goat anti-gp70 antiserum (1:100) for 30 min at 4°C. After
two washes, cells were incubated with 500 µl of secondary antibody,
donkey anti-goat antibody conjugated with fluorescein isothiocyanate
(Jackson Laboratories) diluted in PBA (1:200) for 30 min at 4°C.
Propidium iodide (Sigma) was added to the binding reaction mixture for
5 min at a final concentration of 20 µg/ml. Cells were washed twice
and taken up in 500 µl of PBA, and the fluorescence of 5,000 live
cells (negative for propidium iodide) was analyzed by flow cytometry
(Epics Profile Analyzer; Coulter Cytometry). Experiments were repeated
three times.
Cell-cell fusion assays.
The fusion-from-without assay was
performed as described by Rein and Bassin (24) with
modification as follows. XC cells were exposed to virus stock
containing 20 µg of Polybrene per ml or to medium containing 20 µg
of Polybrene per ml and incubated with continuous exposure at 37°C
for 16 h; then they were fixed and stained with 0.5% methylene
blue-0.16% basic fuchsin in methanol (26). The
fusion-from-within assay was performed as described by Jones and Risser
(12) with the following modifications. Briefly, 60-mm-diameter dishes of 70% confluent 293 cells were transfected with
20 µg of wild-type or mutant pcENV by calcium phosphate
precipitation, at 24 h posttransfection XC cells (106
per dish) were added, and cultures were cocultivated for an additional 24 h. Then cells were stained as described above and observed by
light microscopy.
 |
RESULTS |
We attempted to utilize a genetic selection to generate viruses
containing envelope variants whose analysis would lead to the
identification of critical residues in the virus envelope proteins,
particularly those involved in virus-receptor interactions. For this
selection, we passaged a replication-competent ecotropic virus on human
cells expressing a binding-defective receptor as the only ecotropic
retrovirus receptor present. We chose DHFR-5HE* as the
replication-competent ecotropic virus constructed from proviral clones
of MoMLV for use in these studies. Our choice was based primarily on
the design of the genome of this recombinant virus. It encodes all the
necessary functions for efficient retroviral replication, as well as a
mutant dihydrofolate reductase gene conferring resistance to at least a
30 µM concentration of the drug methotrexate (30) (Fig.
1A). Since infection by laboratory strains of ecotropic retroviruses does not result in any detectable morphological changes in most cultured mammalian cells, the presence of
the selectable marker gene was particularly useful because cells
replicating virus could be selected by growth in medium containing
methotrexate.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Diagram of the proviral genome of the DHFR-5HE*
virus used in the genetic selection on cells expressing defective
ecotropic MLV receptors. In addition to viral gag,
pol, and env genes, the genome encodes a mutant
dihydrofolate reductase (dhfr*) gene, initially introduced
into the unique 3' (U3) region and duplicated into the U3 of the 5'
long terminal repeat (LTR) during virus replication (30).
(B) Defective receptors M-38 and H-63 mediate DHFR-5HE* virus entry as
inefficiently as they mediate ecotropic MoMLV entry. Titers were
determined by endpoint dilution on human 293 cells stably expressing
the receptor cDNA indicated (n = 4). Values are the
averages from three independent experiments.
|
|
The two defective mutants of the ecotropic receptor used for these
studies were M-38 and H-63. M-38 contains a tyrosine-to-proline alteration at residue 235 (Y235P) and an E237V change in the third extracellular domain of the ecotropic receptor, while H-63 contains a
V244E change in the third extracellular domain of the human homolog of
the ecotropic receptor. They were chosen because each is capable of
participating in virus entry but with much less efficiency than that of
the wild-type receptor (1), giving a possible advantage of
several orders of magnitude for an adapted virus. We determined the
titers of our DHFR-5HE*1 (5HE) virus stock on human 293 cells
expressing either the wild-type receptor or one of the defective
receptors. Cells expressing the defective receptors were at least
10,000-fold less susceptible to 5HE virus than were cells expressing
wild-type receptor (Fig. 1B), the same pattern of susceptibility that
we had previously found for replication-defective viruses
(17).
The parental 5HE stock did not contain variants adapted to
defective receptors M-38 and H-63.
Two possibilities could account
for the low level of entry routinely observed in the cells expressing
M-38 and H-63. First, infection might represent the inefficient use of
the defective receptor by wild-type virus. Second, it might involve
infection by a minor variant present in the parental 5HE stock that was capable of using the defective receptor efficiently. To determine if
the latter was the case, we transfected the M-38 or the H-63 cDNAs into
naive human 293 cells and exposed each transfected population to 5HE
virus 3 days later, at which time transient expression of the receptors
would be waning. The exposed cells were then grown in medium containing
methotrexate but not G418 to select for infected cells in the absence
of selection for receptor expression, preventing virus spread so that
each colony would represent only the initial infection event. The 9 methotrexate-resistant colonies and the 15 colonies isolated from
exposed M-38 cells and H-63 cells, respectively, were propagated under
methotrexate selection, and virus-containing supernatants were
harvested from each culture. A comparison of endpoint dilution titers
revealed that none of the viruses produced by the
methotrexate-resistant colonies used the defective receptors better
than did parental 5HE virus stock (data not shown), indicating that the
low level of infection by 5HE stock likely represents inefficient use
of the defective receptors by wild-type virus.
Genetic selection of quasispecies.
We exposed 5 × 105 cells of human cell lines stably expressing either M-38
or H-63 receptors to the 5HE virus stock. A typical exposure led to the
growth of 10 to 20 methotrexate-resistant colonies. Colonies were
pooled and propagated until confluent monolayers were obtained, at
which time their virus-containing supernatant was harvested
(first-passage virus stock) and used to expose fresh cultures of the
same cell line. The virus supernatant exhibited a decline in RT
activity after the first passage on both cell lines. RT activity then
gradually increased to 11- and 7-fold greater than that in the parental
5HE stock after the third passage. Although the RT activity suggested
abundant virus particle production, the titer of the third-passage
stocks on cells expressing the wild-type receptor was low compared to
that of the parental 5HE stock
2,000 and 200 CFU/ml, respectively, for
M-38 and H-63 selected stocks compared to >106 for 5HE
stock. Further passaging on M-38 and H-63 cells did not improve the
apparent number of infectious particles in the virus stocks. Continued
cultivation of the third-passage producer cells in
methotrexate-containing medium resulted in a severalfold increase in RT
activity and increased infectious particle production to greater than
104 CFU/ml. Since cells infected with 5HE virus acquire
resistance to superinfection slowly (30), one explanation
for these observations is that virus production increased upon
continued cultivation of cell populations because cell-to-cell virus
spread increased the number of integrated virus genomes. From each of
these two populations of producer cells, 12 representative
env genes of the quasispecies present after the selection
were isolated, subcloned into the pcDNA MoMLV plasmid, and then
transfected into H1-BAG cells to produce particles that transduce
lacZ and are pseudotyped by the cloned env genes.
Characterization of representative env sequences from
quasispecies present after selection.
Virus stocks generated with
six of the env genes from selection on cells bearing M-38
receptors and four env genes from selection on H-63
receptors were as infectious as wild-type MoMLV, suggesting that these
Env proteins either were unaltered or contained innocuous changes (data
not shown). The remaining 14 stocks were at least 100-fold less
infectious than MoMLV. The decrease in infectivity might be the result
of poor transfection efficiency during virus production, poor
incorporation of Env into virions, or changes in Env residues critical
to interaction with the receptor. To distinguish between these
possibilities, virus from equal volumes of transfected H1-BAG cell
supernatant was pelleted through a sucrose cushion and Western blot
analysis was performed with anti-SU and anticapsid antiserum. For
comparison, we also analyzed supernatant from cells transfected with
the pcDNA MoMLV plasmid containing wild-type env and with
plasmid containing env clone 832 that produced highly
infectious particles. Aliquots of each supernatant were removed prior
to centrifugation and used for endpoint dilution titration on naive NIH
3T3 cells and human cells expressing the wild-type receptor (Fig.
2A).

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 2.
The reduction in infectivity of virus variants is
predominantly due to lack of envelope protein incorporation into
virions. (A) Naive NIH 3T3 cells (stippled bars) or 293 cells stably
expressing the wild-type ecotropic MLV receptor (black bars) were
exposed to 10-fold serial dilutions of virus stocks containing virions
pseudotyped with envelope proteins encoded on the 14 cloned
env genes that showed reduced infectivity. Titers were
calculated from the endpoint dilution (n = 4). Values
are the averages from four independent experiments. Titers of viruses
with Env from clones 871, 875, and 877 were less than 1 on NIH 3T3
cells. MoMLV, wild-type ecotropic MoMLV; mock, mock-transfected cells.
(B) Western blot analysis of virions containing cloned env
genes. Viral proteins were separated by SDS-polyacrylamide gel
electrophoresis on 8% polyacrylamide gels. Membranes were cut in two
parts at the position indicated by the black line, roughly that of the
45-kDa molecular mass standard. The top portion was probed with anti-SU
antisera, and the bottom was probed with anticapsid (CA) antisera. The
immunoblot shown is representative of four made from independent virus
preparations. (C) Western blot analysis of virus producer cell lysates.
Proteins were separated on 8% polyacrylamide gels, and membranes were
probed with anti-SU antisera.
|
|
Upon short exposure of immunoblots, the intensities of the bands
corresponding to capsid protein were within twofold of each other in
all pellets, except those from mock-transfected cells (data not shown),
indicating that transfection efficiencies were comparable. The majority
of cloned env sequences encoded proteins that were very
poorly incorporated into virions (Fig. 2B). Steady-state levels of Env
in lysates of the producer cells transfected with clones 837, 857, 871, 879, 891, and 895 were too low to be detected (Fig. 2C), indicating
that low infectivity resulted from poor incorporation of unstable
envelope proteins. Env from clones 829, 865, and 877 showed evidence of
either truncated forms or degradation products of SU in cell lysates.
Notably, Env from clones 855 and 875 showed evidence of
less-than-normal cleavage of precursor protein into mature SU (Fig.
2C), and virions contained a slightly larger species that was the size
of envelope precursor protein. All virus stocks, including wild-type
MoMLV, consistently exhibited a 4- to 20-fold-greater titer on 293 cells expressing receptor than on NIH 3T3 cells, suggesting that the
difference in infection results from a property of the host cell line
rather than of the virus. For instance, the 293 receptor cell line has
a greater number of virus binding sites than do NIH 3T3 cells
(1a), a feature that might account for this difference.
We focused further analyses on clones 838 and 839 encoding Env proteins
that were processed normally and efficiently incorporated into virions
but showed a 100-fold reduction in infectivity (Fig. 2). In addition,
we continued analysis of clone 881 because its steady-state levels of
expression and processing appeared normal but its incorporation into
virions was very poor (Fig. 2). The DNA sequence of these three clones
was determined, and the sequence of the encoded protein was deduced
from it. The sequence of the envelope gene from DHFR-5HE* was
determined for comparison. It was identical to the published sequence
of MoMLV (29) from which it was derived. env
clone 881 encodes a single substitution of proline for serine (T
C at
nucleotide 7361) at position 60 in the putative leucine zipper domain
of TM.
Replacement of glutamine 227 and aspartate 243 can suppress a
defect in infection caused by replacement of histidine 8 of SU.
Clones 838 and 839 were identical in sequence; they encoded the same
three alterations of histidine 8 to arginine (H8R; A
G at nucleotide
5898), glutamine 227 to arginine (Q227R; A
G at nucleotide 6555), and
aspartate 243 to tyrosine (D243Y; G
T at nucleotide 6602). We placed
these changes in the wild-type env sequences as single
mutations or as all combinations of substitutions to determine which is
responsible for the decrease in infectivity. Figure
3 shows the results of the
characterization of the encoded proteins. A single H8R substitution
almost completely abolished infection, while single and double
mutations at the other two positions did not affect infection (Fig.
3A). These results indicate that the change in histidine 8 is
responsible for the reduced infection found with clones 838 and 839. Interestingly, the triple mutation corresponding to the original 838 and 839 clones was only 100-fold less infectious than wild-type virus,
suggesting that one of the other two mutations can suppress the defect
introduced by the change of histidine 8. However, neither a Q227R nor a
D243Y mutation in combination with an H8R mutation improved infectivity appreciably, indicating that both changes are required and that they
exert a synergistic effect on the H8R mutation.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 3.
A histidine-8-to-arginine mutation introduces a defect
in virus entry that is overcome by the synergistic action of amino acid
substitutions at positions 227 and 243. (A) Infectious titers on NIH
3T3 cells (stippled bars) and 293 cells expressing exogenous wild-type
receptor (black bars). Titers were calculated from the endpoint
dilution (n = 4) after exposure to virions pseudotyped
with envelope proteins containing the indicated substitutions. Each
value is the average from five independent experiments. The titer of
H8R virus on NIH 3T3 cells was less than 1 in all experiments. (B)
Western blot analysis of virions containing mutant envelope proteins.
Proteins were separated on a 12% polyacrylamide gel. The membrane was
cut into three parts at the positions indicated by the black lines,
roughly that of the 45- and 25-kDa molecular mass standards. The top
portion was incubated with anti-SU antisera, the middle portion was
incubated with anti-CA antisera, and the bottom part was incubated with
anti-TM antisera. The immunoblot shown is representative of five made
from independent virus preparations. (C) Western blot analysis of virus
producer cell lysates. Proteins were separated on 8% polyacrylamide
gels and then blotted to anti-SU antisera. Numbers at left of panels B
and C show molecular mass in kilodaltons.
|
|
The defect in virus entry is at the level of fusion and can be
suppressed by the changes in residues 227 and 243.
All of the
mutant envelope proteins were efficiently incorporated into virions
(Fig. 3B) and processed normally (Fig. 3C), indicating that the
reduction in infectivity of H8R viruses was not due to lack of
expression on producer cells or to failure to incorporate into virions.
Therefore, it was likely that mutation of histidine 8 abolished a
function of the envelope involved in virus entry. We performed binding
and fusion assays to determine if virus binding or virus penetration of
the host cell membrane was affected.
Viruses pseudotyped in H8R Env bound human cells expressing receptor as
proficiently as did wild-type MoMLV (Fig.
4, left panels), indicating that
histidine 8 is not involved in virus attachment and suggesting that it
is involved in a downstream entry step. Following virus binding, the
envelope protein induces fusion of viral and cellular membranes to
release the nucleocapsid into the cytoplasm. Because direct measurement
of the fusogenic potential of an envelope protein during virus-cell
fusion is difficult, indirect cell-cell fusion assays using XC cells
have been widely used (3, 12, 23). XC cells express the
ecotropic retrovirus receptor on their surface and are susceptible to
MLV infection. In addition, they exhibit an extraordinary propensity to
undergo cell-cell fusion when exposed to wild-type MLV (fusion from
without) or when cocultivated with cells expressing virus envelope
(fusion from within) (12, 24). This ability to induce
syncytium on XC cells has been utilized to evaluate the fusion
properties of the envelope proteins of ecotropic viruses (3, 12,
23, 33). We performed fusion assays with XC cells and found that viruses pseudotyped with H8R Env failed to induce XC cell fusion in the
same assay in which wild-type virus induced extensive fusion (Fig. 4,
middle panels). Cells expressing this Env mutant also failed to
participate in fusion with XC cells (Fig. 4, right panels). In
contrast, the presence of the Q227R and D243Y mutations suppressed the
H8R mutation, partially restoring syncytium-inducing capability in both
the fusion-from-without and the fusion-from-within assays. These
results suggest that histidine 8 of SU plays an essential role in
virus-cell fusion and imply that its role can be replaced by
substitution of glutamine 227 and aspartate 243. It is noteworthy that
in the absence of any change at residue 8, the ability of Q227R D243Y
Env to induce cell-cell fusion was compromised. XC cells exposed to
Q227R D243Y virions and XC cells cocultivated with Q227R D243Y
Env-expressing cells exhibited numerous small syncytia in contrast to
the extensive syncytia induced by wild-type protein, even though the
Q227R D243Y particles were as infectious as MoMLV. This reduction in
the size of syncytium might explain why the suppressing mutations do
not completely restore fusion function and infectivity to an H8R
mutant.

View larger version (112K):
[in this window]
[in a new window]
|
FIG. 4.
Replacement of histidine 8 with arginine results in a
defect in envelope fusion function that is suppressed by the
glutamine-227-to-arginine and aspartate-243-to-tyrosine mutations.
(Left panels) Virus binding. Dashed line, binding of wild-type virus to
293 cells lacking receptor; dotted line, nonspecific binding of
antisera in the absence of virus to 293 cells stably expressing
receptor. Shaded area represents binding of wild-type or mutant viruses
to the 293 cells expressing receptor. (Middle panels) Fusion from
without. XC rat sarcoma cells were exposed to virions pseudotyped with
the envelope protein indicated. Induced syncytia were stained with
methylene blue and basic fuchsin. (Right panels) Fusion from within. XC
cells were cocultivated with 293 cells expressing the indicated Env.
Mock, mock-infected XC cells; pcDNA3, XC cells cocultivated with 293 cells expressing vector pcDNA3. Arrows in H8R Q227R D243Y panels point
to syncytium. H8R, histidine 8 to arginine; Q227R, glutamine 227 to
arginine; D243Y, aspartate 243 to tyrosine.
|
|
 |
DISCUSSION |
Using a genetic selection similar to that used by other groups to
obtain variants adapted to mutant receptors, soluble receptors, or
inhibitory drugs (18, 21, 22), we did not obtain a virus variant that utilized the defective receptors more efficiently than did
wild-type virus (34a). It may not be possible to complement the precise changes present in these defective receptors either because
no amino acid in SU can reestablish the required interaction or because
any change that can reestablish that interaction is deleterious to
envelope folding, processing, or stability. Alternately, the desired
complementing changes might be somewhat deleterious, allowing only a
low level of expression of Env on the cell surface that leads to poor
incorporation into virions. Such an outcome might well counteract any
benefit obtained from a stronger binding to the defective receptor and
interfere with enrichment for viruses bearing that envelope variant. We
did not analyze enough envelope sequences to draw conclusions about
either possibility.
Although we did not isolate a variant adapted to any of the mutant
receptors, we did isolate a number of mutant env genes encoding proteins with interesting properties. Analysis of these mutants provided new insights into regions of Env that are essential for its assembly and productive virus-receptor interactions. It is
unclear what role the defective receptors played in selection of these
particular env genes, as it might also be possible to isolate the same variants by virus passaging on cells expressing a
functional receptor. Envelope clone 881 contained a point mutation resulting in a serine-to-proline mutation at position 60 of TM. Residues 46 through 78 of TM form an alpha-helical structure that is
the putative coiled-coil oligomerization domain for the envelope trimer
(9). In the Saccharomyces cerevisiae two-hybrid
system, this segment acts as a dimerization domain (15).
When prolines were placed in the analogous domain of human
immunodeficiency virus TM, the contact site between SU and TM was
disrupted and virions did not incorporate envelope proteins
(4). However, when amino acid substitutions other than
proline were placed in this domain of MoMLV or human immunodeficiency
virus, Env incorporation and virus binding were normal but virions were
fusion defective, suggesting that this is a domain involved in fusion
and not an oligomerization domain (5, 23, 34). Our data show
that a serine 60-to-proline change in this domain markedly decreases the amount of Env on virions, supporting the former results. The strong
helix-breaking properties of proline might induce changes in structure
that interfere with or weaken envelope trimerization and/or association
of SU and TM, resulting in poor assembly of the encoded protein into virions.
SU contains a domain essential to the fusion function of envelope
protein.
Changes in glutamine 227 and aspartate 243 acted
synergistically on the mutation at histidine 8, suggesting that they
suppress the H8R mutation by compensating for the same essential
function of that residue. It is striking that residues so distant on
the peptide chain of SU can influence each other's function,
suggesting that they might be adjacent in the folded protein. Moreover,
it was previously thought that the functional domains involved in virus
binding reside in SU while virus-cell fusion domains reside in TM.
However, recent deletion analysis of SU revealed that removing residues
2 through 8 almost completely abolished infectivity (3). Replacement of histidine 8 with alanine, glutamate, or lysine, as well
as deletion of that position, dramatically reduced infection and
completely abolished Env-mediated XC cell fusion but did not affect
virus binding (3). These results suggested that the aromatic
side chain of histidine 8 plays a critical role in Env-mediated fusion.
Bae and coworkers (3) suggested that histidine 8 is a
critical residue in an amino-terminal fusion domain consisting of the
first eight residues of SU. Our independent identification of the role
of histidine 8 in virus-cell fusion confirms the importance of that
residue in fusion. However, it is not clear that residues 2 to 7 are
also members of the histidine 8 fusion domain. The 20-fold reduction in
fusion found by Bae and colleagues upon deletion of amino acids 2 to 7 might be due to structural changes in the proximity of histidine 8 that
occur when the adjacent residues are missing, not to loss of function
of these residues. Instead of belonging to a contiguous domain,
histidine 8 might be an essential member of a noncontiguous,
three-dimensional fusion domain. Some insights into the composition of
such a domain may be found in the phenotype of the Q227R D243Y Env
mutant. Q227R D243Y Env induced markedly reduced levels of fusion from
within and fusion from without, indicating that these two residues can
profoundly influence Env fusion properties possibly by producing subtle
conformational changes in adjacent residues that are constituents of
the histidine 8 fusion domain.
A model for the mechanism of suppression of the fusion defect.
The recent solution of the crystal structure of an amino-terminal
fragment of ecotropic FrMLV (8), an ecotropic MLV closely related to MoMLV, provides insights into our findings. The three residues are conserved between the Moloney and Friend viruses: a
histidine occupies the eighth position in FrMLV SU, while glutamine 229 of FrMLV corresponds to MoMLV 227, and aspartate 245 of FrMLV corresponds to MoMLV 243. Since the first eight residues were not in
the structure of FrMLV SU, presumably because their conformation is
variable, and the crystallized fragment ended at residue 236, we must
speculate as to the positions of two of the three critical residues.
Figure 5 shows a speculative model of the
mechanism of suppression of the fusion defect. The space where the
imidazole ring of histidine 8 would be expected to lie adjacent to
glutamine 9 is directly next to the charged side group of the residue
corresponding to arginine 232 (Fig. 5, left panel). In the mutant,
repulsion between the guanadino groups of arginines 8 and 232 might
displace one of the two side chains, presumably that of position 8 because this region of the peptide chain appears to be flexible,
leaving an opening into which another aromatic side chain might slip
(Fig. 5, right panel). The residue corresponding to glutamine 227 lies at the carboxy-terminal end of a
-strand consisting of alternating hydrophobic residues and polar or charged amino acids (residues 218 to
227 [Fig. 5]). This
-strand changes from
LTFGIRLRYQ
to LTFGIRLRYR
in the mutant, adding another repeat of hydrophobic (italics) and
charged or polar (underlined) residues. If this change extended the
-strand by one residue, then the peptide chain might twist slightly,
repositioning the downstream residues including residue 243. Thus,
placing arginines at positions 8 and 227 might cause structural changes
that bring the aromatic ring of the tyrosine at position 243 close
enough to the position normally occupied by the aromatic ring of
histidine 8 to provide the required contribution to fusion. This model
is consistent with our results in that it predicts the synergistic
action of the suppressing mutations. It also predicts that the double
H8R Q227R and H8R D243Y mutants should be almost as defective as the H8R mutant and that fusion might be compromised in a Q227R D243Y mutant
even though there is a histidine in position 8.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 5.
A speculative model of the mechanism of suppression of
the fusion defect. (Left panel) The diagram of the structure of
residues 9 to 234 (bright colors) of the wild-type MoMLV SU was
generated with the crystal structure coordinates of the closely related
FrMLV surface protein (8) in the RasMol visualization
program, based on the assumption that the structure is conserved
between MoMLV and FrMLV SU because they have 89% amino acid identity
and 97% conservation in this region. Residues 8, 12, 84, 227, 232, and
243 are represented as space-filled amino acids; the remaining residues
are represented in the ribbon model. The structure of residues 1 to 8 and 235 to 245 (muted colors) is hypothetical. The amino-terminal eight
residues were presumed to form a random coil. Residues 235 to 239 (IGPNP) were modeled as a turn and residues 240 to 245 (VLADQQ) were
modeled as a -strand based on the structures predicted by the
Chou-Fasman and Garnier-Robson algorithms, respectively, of the Protean
program of DNASTAR sequence analysis. (Right panel) Diagram of the
hypothetical structure of the H8R Q227R D243Y mutant. Arrows indicate
the direction of side chain repositioning resulting from placing
arginines at positions 8 and 227. The perspective is from the side
opposite from that in the left panel to show putative side chain
interactions between mutated residues 8 and 243.
|
|
MoMLV particles are readily pseudotyped with virtually all other
retroviral envelope proteins so that they utilize the receptor specified by the heterologous SU. This promiscuity with respect to
envelope incorporation has been exploited to develop retroviral vectors
for use in targeted human gene therapy. However, the modified viruses
developed for this use are very poorly infectious or completely noninfectious and thus not practical for use in gene delivery. Others
have suggested that a major source of their poor infectivity is a
defect in the ability of these modified envelope proteins to perform
postbinding events, particularly fusion (7, 27, 32, 35). It
is noteworthy that in these targeted envelope proteins, the sequences
to direct binding of the virus to a new receptor were either inserted
within the first 20 residues of SU or used to replace the amino
terminus. The latter design deletes the essential histidine side chain
while the insertions likely change its position, producing essentially
the same defect as that caused by the H8R mutation. Thus, it might be
possible to dramatically increase the infectivity of these targeted
retroviral vectors by constructing them with an envelope with the
suppressing arginine and tyrosine substitutions at positions 227 and
243, respectively.
 |
ACKNOWLEDGMENTS |
We thank Heidi Stuhlmann for providing the DHFR-5HE* virus; Alan
Rein for providing the anti-TM antiserum; and Krish Kizhatil, Zhaohui
Qian, and Byoung Ryu for critical reading of the manuscript.
This work was supported by Public Health Service grant AI33410 from the
National Institutes of Health (to L.M.A.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of Tennessee
Memphis, 858 Madison Ave., Rm. 101, Memphis, TN 38163. Phone: (901) 448-5521. Fax: (901) 448-8462. E-mail: lalbritton{at}utmem.edu.
 |
REFERENCES |
| 1.
|
Albritton, L. M.,
J. W. Kim,
L. Tseng, and J. M. Cunningham.
1993.
Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses.
J. Virol.
67:2091-2096[Abstract/Free Full Text].
|
| 1a.
| Albritton, L. M., and K. Kizhatil. Unpublished
data.
|
| 2.
|
Albritton, L. M.,
L. Tseng,
D. Scadden, and J. M. Cunningham.
1989.
A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection.
Cell
57:659-666[Medline].
|
| 3.
|
Bae, Y.,
S. M. Kingsman, and A. J. Kingsman.
1997.
Functional dissection of the Moloney murine leukemia virus envelope protein gp70.
J. Virol.
71:2092-2099[Abstract].
|
| 4.
|
Chen, S. S.-L.
1994.
Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein.
J. Virol.
68:2002-2010[Abstract/Free Full Text].
|
| 5.
|
Chen, S. S.-L.,
C.-N. Lee,
W.-R. Lee,
K. McIntosh, and T.-H. Lee.
1993.
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein.
J. Virol.
67:3615-3619[Abstract/Free Full Text].
|
| 6.
|
Coffin, J. M.,
S. H. Hughes, and H. E. Varmus.
1997.
Retroviruses.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 7.
|
Cosset, F. L.,
F. J. Morling,
Y. Takeuchi,
R. A. Weiss,
M. K. L. Collins, and S. J. Russell.
1995.
Retroviral retargeting by envelopes expressing an N-terminal binding domain.
J. Virol.
69:6314-6322[Abstract].
|
| 8.
|
Fass, D.,
R. A. Davey,
C. A. Hamson,
P. S. Kim,
J. M. Cunningham, and J. M. Berger.
1997.
Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution.
Science
277:1662-1666[Abstract/Free Full Text].
|
| 9.
|
Fass, D.,
S. C. Harisson, and P. S. Kim.
1996.
Retrovirus envelope domain at 1.7A resolution.
Nat. Struct. Biol.
3:465-469[Medline].
|
| 10.
|
Goff, S.,
P. Traktman, and D. Baltimore.
1981.
Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.
J. Virol.
38:239-248[Abstract/Free Full Text].
|
| 11.
|
Harbers, K.,
A. Schnieke,
H. Stuhlman,
D. Jahner, and R. Jaenish.
1981.
DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning.
Proc. Natl. Acad. Sci. USA
78:7609-7613[Abstract/Free Full Text].
|
| 12.
|
Jones, J. S., and R. Risser.
1993.
Cell fusion induced by the murine leukemia virus envelope glycoprotein.
J. Virol.
67:67-74[Abstract/Free Full Text].
|
| 13.
|
Kadan, M. J.,
S. Sturm,
W. F. Anderson, and M. A. Eglitis.
1992.
Detection of receptor-specific murine leukemia virus binding to cells by immunofluorescence analysis.
J. Virol.
66:2281-2287[Abstract/Free Full Text].
|
| 14.
|
Kunkel, T. A.
1985.
Rapid and efficient site specific mutagenesis without phenotypic selection.
Proc. Natl. Acad. Sci. USA
82:477-492.
|
| 15.
|
Li, X.,
B. McDermott,
B. Yuan, and S. Goff.
1996.
Homomeric interactions between transmembrane proteins of Moloney murine leukemia virus.
J. Virol.
70:1266-1270[Abstract].
|
| 16.
|
MacKrell, A. J.,
N. W. Soong,
C. M. Curtis, and W. F. Anderson.
1996.
Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding.
J. Virol.
70:1768-1774[Abstract].
|
| 17.
|
Malhotra, S.,
A. G. Scott,
T. Zavorotinskaya, and L. M. Albritton.
1996.
Analysis of the murine ecotropic leukemia virus receptor reveals a common biochemical determinant on diverse cell surface receptors that is essential to retrovirus entry.
J. Virol.
70:321-326[Abstract].
|
| 18.
|
Martin, A.,
C. Wychowski,
T. Couderc,
R. Crainic,
J. Ogle, and M. Girard.
1988.
Engineering a poliovirus type 2 antigenic site or a type 1 capsid results in a chimeric virus, which is neurovirulent for mice.
EMBO J.
7:2839-2847[Medline].
|
| 19.
|
Masuda, M.,
M. Masuda,
C. A. Hanson,
P. M. Hoffman, and S. K. Ruscetti.
1996.
Analysis of the unique hamster cell tropism of ecotropic murine leukemia virus PVC-211.
J. Virol.
70:8534-8539[Abstract].
|
| 20.
|
Miller, A. D.,
M.-F. Law, and I. M. Verma.
1985.
Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene.
Mol. Cell. Biol.
5:431-437[Abstract/Free Full Text].
|
| 21.
|
Moss, E., and V. Racaniello.
1991.
Host range determinants located on the anterior of the poliovirus capsid.
EMBO J.
10:1067-1074[Medline].
|
| 22.
|
Murray, M.,
J. Bradley,
X. Yang,
E. Wimmer,
E. Moss, and V. Racaniello.
1988.
Poliovirus host range is determined by a short amino acid sequence in neutralization of antigenic site 1.
Science
241:213-215[Abstract/Free Full Text].
|
| 23.
|
Ramsdale, E. E.,
S. M. Kingsman, and A. J. Kingsman.
1996.
The "putative" leucine zipper region of murine leukemia virus transmembrane protein is essential for viral infectivity.
Virology
220:100-108[Medline].
|
| 24.
|
Rein, A., and R. H. Bassin.
1978.
Replication-defective ecotropic murine leukemia viruses: detection and quantitation of infectivity using helper-dependent XC plaque formation.
J. Virol.
28:656-660[Abstract/Free Full Text].
|
| 25.
|
Rein, A.,
B. I. Gerwin,
R. H. Bassin,
L. Schwarm, and G. Schidlovsky.
1978.
A replication defective variant of Moloney murine leukemia virus.
J. Virol.
25:146-156[Abstract/Free Full Text].
|
| 26.
|
Rein, A.,
J. Mirro,
J. G. Haynes,
S. M. Ernst, and K. Nagashima.
1994.
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein.
J. Virol.
68:1773-1781[Abstract/Free Full Text].
|
| 27.
|
Rein, A.,
C. Yang,
J. A. Haynes,
J. Mirro, and R. W. Compans.
1998.
Evidence for cooperation between murine leukemia virus Env molecules in mixed oligomers.
J. Virol.
72:3432-3435[Abstract/Free Full Text].
|
| 28.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 29.
|
Shinnick, K.,
R. A. Lerner, and J. G. Sutcliffe.
1981.
Nucleotide sequence of Moloney murine leukemia virus.
Nature
293:543-548[Medline].
|
| 30.
|
Stuhlmann, H.,
R. Jaenisch, and R. Mulligan.
1989.
Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance.
Mol. Cell. Biol.
9:100-108[Abstract/Free Full Text].
|
| 31.
|
Turner, D. L., and C. L. Cepko.
1987.
A common progenitor for neuron and glia persists in rat retina late in development.
Nature
328:131-136[Medline].
|
| 32.
|
Valsesia-Wittmann, S.,
A. Drynda,
G. Deleage,
M. Aumailley,
M. Heard,
O. Danos,
G. Verdier, and F. Cosset.
1994.
Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.
J. Virol.
68:4609-4619[Abstract/Free Full Text].
|
| 33.
|
Weiss, R.,
N. Teich,
H. Varmus, and J. Coffin.
1984.
RNA tumor viruses.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 34.
|
Wild, C.,
J. W. Dubay,
T. Greenwell,
T. J. Baird,
T. G. Oas,
C. McDanal,
E. Hunter, and T. Matthews.
1994.
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.
Proc. Natl. Acad. Sci. USA
91:12676-12680[Abstract/Free Full Text].
|
| 34a.
| Zavorotinskaya, T. Unpublished results.
|
| 35.
|
Zhao, Y.,
S. Lee, and W. F. Anderson.
1997.
Functional interactions between monomers of the retroviral envelope protein complex.
J. Virol.
71:6967-6972[Abstract].
|
Journal of Virology, June 1999, p. 5034-5042, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ryu, B. Y., Zavorotinskaya, T., Trentin, B., Albritton, L. M.
(2008). The block to membrane fusion differs with the site of ligand insertion in modified retroviral envelope proteins. J. Gen. Virol.
89: 1049-1058
[Abstract]
[Full Text]
-
Cheng, H. H., Anderson, M. M., Hankenson, F. C., Johnston, L., Kotwaliwale, C. V., Overbaugh, J.
(2006). Envelope Determinants for Dual-Receptor Specificity in Feline Leukemia Virus Subgroup A and T Variants. J. Virol.
80: 1619-1628
[Abstract]
[Full Text]
-
Viejo-Borbolla, A., Thomas, P., Blair, E. D., Schulz, T. F.
(2005). Increase in infectivity of targeted Moloney murine leukemia virus-based gene-delivery vectors through lowering the threshold for fusion. J. Gen. Virol.
86: 2469-2480
[Abstract]
[Full Text]
-
Lavillette, D., Kabat, D.
(2004). Porcine Endogenous Retroviruses Infect Cells Lacking Cognate Receptors by an Alternative Pathway: Implications for Retrovirus Evolution and Xenotransplantation. J. Virol.
78: 8868-8877
[Abstract]
[Full Text]
-
Qian, Z., Wang, H., Empig, C., Anderson, W. F., Albritton, L. M.
(2004). Complementation of a Binding-Defective Retrovirus by a Host Cell Receptor Mutant. J. Virol.
78: 5766-5772
[Abstract]
[Full Text]
-
Zavorotinskaya, T., Qian, Z., Franks, J., Albritton, L. M.
(2004). A Point Mutation in the Binding Subunit of a Retroviral Envelope Protein Arrests Virus Entry at Hemifusion. J. Virol.
78: 473-481
[Abstract]
[Full Text]
-
Qian, Z., Albritton, L. M.
(2004). An Aromatic Side Chain Is Required at Residue 8 of SU for Fusion of Ecotropic Murine Leukemia Virus. J. Virol.
78: 508-512
[Abstract]
[Full Text]
-
O'Reilly, L., Roth, M. J.
(2003). G541R within the 4070A TM Protein Regulates Fusion in Murine Leukemia Viruses. J. Virol.
77: 12011-12021
[Abstract]
[Full Text]
-
Lu, C.-W., Roth, M. J.
(2003). Role of the Mutation Q252R in Activating Membrane Fusion in the Murine Leukemia Virus Surface Envelope Protein. J. Virol.
77: 10841-10849
[Abstract]
[Full Text]
-
Qian, Z., Donald, R., Wang, H., Chen, Q., Albritton, L. M.
(2003). Identification of a Critical Basic Residue on the Ecotropic Murine Leukemia Virus Receptor. J. Virol.
77: 8596-8601
[Abstract]
[Full Text]
-
Lu, C.-W., O'Reilly, L., Roth, M. J.
(2002). G100R Mutation within 4070A Murine Leukemia Virus Env Increases Virus Receptor Binding, Kinetics of Entry, and Viral Transduction Efficiency. J. Virol.
77: 739-743
[Abstract]
[Full Text]
-
Lavillette, D., Ruggieri, A., Boson, B., Maurice, M., Cosset, F.-L.
(2002). Relationship between SU Subdomains That Regulate the Receptor-Mediated Transition from the Native (Fusion-Inhibited) to the Fusion-Active Conformation of the Murine Leukemia Virus Glycoprotein. J. Virol.
76: 9673-9685
[Abstract]
[Full Text]
-
Lauring, A. S., Cheng, H. H., Eiden, M. V., Overbaugh, J.
(2002). Genetic and Biochemical Analyses of Receptor and Cofactor Determinants for T-Cell-Tropic Feline Leukemia Virus Infection. J. Virol.
76: 8069-8078
[Abstract]
[Full Text]
-
Farrell, K. B., Ting, Y.-T., Eiden, M. V.
(2002). Fusion-Defective Gibbon Ape Leukemia Virus Vectors Can Be Rescued by Homologous but Not Heterologous Soluble Envelope Proteins. J. Virol.
76: 4267-4274
[Abstract]
[Full Text]
-
Kizhatil, K., Gromley, A., Albritton, L. M.
(2001). Two Point Mutations Produce Infectious Retrovirus Bearing a Green Fluorescent Protein-SU Fusion Protein. J. Virol.
75: 11881-11885
[Abstract]
[Full Text]
-
Lauring, A. S., Anderson, M. M., Overbaugh, J.
(2001). Specificity in Receptor Usage by T-Cell-Tropic Feline Leukemia Viruses: Implications for the In Vivo Tropism of Immunodeficiency-Inducing Variants. J. Virol.
75: 8888-8898
[Abstract]
[Full Text]
-
Valsesia-Wittmann, S.
(2001). Role of Chimeric Murine Leukemia Virus env {beta}-Turn Polyproline Spacers in Receptor Cooperation. J. Virol.
75: 8478-8486
[Abstract]
[Full Text]
-
Lu, C.-W., Roth, M. J.
(2001). Functional Characterization of the N Termini of Murine Leukemia Virus Envelope Proteins. J. Virol.
75: 4357-4366
[Abstract]
[Full Text]
-
Lavillette, D., Boson, B., Russell, S. J., Cosset, F.-L.
(2001). Activation of Membrane Fusion by Murine Leukemia Viruses Is Controlled in cis or in trans by Interactions between the Receptor-Binding Domain and a Conserved Disulfide Loop of the Carboxy Terminus of the Surface Glycoprotein. J. Virol.
75: 3685-3695
[Abstract]
[Full Text]
-
Gwynn, S. R., Hankenson, F. C., Lauring, A. S., Rohn, J. L., Overbaugh, J.
(2000). Feline Leukemia Virus Envelope Sequences That Affect T-Cell Tropism and Syncytium Formation Are Not Part of Known Receptor-Binding Domains. J. Virol.
74: 5754-5761
[Abstract]
[Full Text]
-
Lavillette, D., Ruggieri, A., Russell, S. J., Cosset, F.-L.
(2000). Activation of a Cell Entry Pathway Common to Type C Mammalian Retroviruses by Soluble Envelope Fragments. J. Virol.
74: 295-304
[Abstract]
[Full Text]
-
Zavorotinskaya, T., Albritton, L. M.
(1999). A Hydrophobic Patch in Ecotropic Murine Leukemia Virus Envelope Protein Is the Putative Binding Site for a Critical Tyrosine Residue on the Cellular Receptor. J. Virol.
73: 10164-10172
[Abstract]
[Full Text]